Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form.

2. (Original) The substantially crystalline form as claimed in claim 1 in the form of needle-shaped crystals.

3. (Original) The substantially crystalline form as claimed in claim 1 in the form of lath-shaped crystals.

4. (Original) The substantially crystalline form as claimed in claim 1 in the form of a mixture of needle-shaped and lath-shaped crystals.

5. (Previously Presented) The substantially crystalline form as claimed in claim 1 wherein the melting point is greater than 160°C.

6. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1-9.2 (±0.1), 16.0-16.1 (±0.1), 18.0-18.2 (±0.1), and 18.3-18.4 (±0.1) degrees.

7. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.21 ±0.05, 13.79 ±0.05, 16.11 ±0.05, 18.11±0.05, and 18.39 ±0.05 degrees.

8. (Original) The substantially crystalline form as claimed in claim 1 having an X-ray powder diffraction pattern expressed in terms of 2 theta angles and obtained with a diffractometer, wherein said X-ray powder diffraction pattern comprises 2 theta angles at one or more positions selected from the group consisting of 9.1 ±0.1, 16.0 ±0.1, 18.0 ±0.1, and 18.3 ±0.1 degrees.

9. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction data are as shown in Table 2.

10. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction data are as shown in Table 4.

11. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction pattern is as shown in Figure 1.

12. (Original) The substantially crystalline form as claimed in claim 1 for which the X-ray diffraction pattern is as shown in Figure 2.

13. (Previously Presented) A method for the preparation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form which method comprises crystallisation of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide from an organic solution, optionally in the presence of water.

14. (Original) A method as claimed in claim 13 wherein the organic solution selected from: an aromatic hydrocarbon, a cycloalkane, an ester, an alcohol or a ketone, or a mixture thereof.

15. (Cancelled).

16. (Cancelled).

17. (Cancelled).

18. (Cancelled).